Last reviewed · How we verify
NCT01850745
Evaluation of a multidìsciplinary Support Program in the Adherence and Efficacy of Peginterferon Alfa-2a and Ribavirin Therapy in Chronic Hepatitis C.
trial testing Multidisciplinary support program in Hepatitis C, Chronic in 447 participants. Completed in 1 January 2010.
1 January 2009
Quick facts
| Lead sponsor | Parc de Salut Mar |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 447 |
| Start date | 1 January 2003 |
| Primary completion | 1 January 2009 |
| Estimated completion | 1 January 2010 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Multidisciplinary support program
Conditions studied
- Hepatitis C, Chronic — all drugs for Hepatitis C, Chronic →
Sponsor
Parc de Salut Mar — full company profile →
Who can join
18 and older, any sex, with Hepatitis C, Chronic. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Adherence to Treatment
Time frame: 48 months
Adherent patients were defined as those receiving equal or more than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during equal o more than 80% of duration treatment (48 weeks). Non-adherent patients were defined as those receiving less than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during less than 80% of duratio
Sponsor's own description
Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to achieve sustained virological response (SVR). The aim of our study is to evaluate the efficacy of a multidisciplinary support program (MSP) in adherence to and efficacy of pegylated interferon alfa-2a and ribavirin compared to the conventional approach. We assessed 447 patients with CHC receiving antiviral treatment distributed into 3 groups: control group (recruited 2002-2004, n= 147), MSP-pilot group (recruited 2005-2006, n=131), and MSP-validation group (recruited 2007-2009, n=169).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01850745
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Multidisciplinary support program
Trials testing the same drug.
- NCT07249294 — Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease · NA · active not recruiting
Other recruiting trials for Hepatitis C, Chronic
Currently open trials in the same condition.
- NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting
- NCT04943588 — Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs · recruiting
- NCT03520660 — People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents · Phase 4 · active not recruiting
- NCT03200379 — Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan · recruiting
Other Parc de Salut Mar trials
Trials by the same sponsor.
- NCT06163235 — Efficacy of a Mobile Application and Semi-attendance Program in Bariatric Surgery · NA · not yet recruiting
- NCT07223450 — A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling · Phase 1 · completed
- NCT07504913 — Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 · recruiting
- NCT06806072 — BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY · NA · not yet recruiting
- NCT04084795 — Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01850745 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Parc de Salut Mar
- Last refreshed: 15 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01850745.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing